HELIX BIOPHARMA Aktie

 

  (Toronto, Ontario) – Helix BioPharma Corp. - TheNewswire - (TSX: “HBP”, OTC PINK: “HBPCD”, FRANKFURT: “HBP0”) (“Helix” or the “Company”), a clinical-stage oncology company shaping a near future where today's hard-to-treat cancers are vincible, announces the filing of the Company's unaudited interim financial statements as of and for the nine month period ended April 30, 2025 (the “Financial Statements”), the management's discussion and analysis (“MD&A”), and the certifications of the Chief Executive Officer and Chief Financial Officer (respectively, “CEO” and “CFO”) relating to the Financial Statements (collectively, the “Interim Filings”). The Interim Filings are available on the Company's profile at www.sedarplus.ca.     About Helix BioPharma Helix BioPharma is an oncology company that innovates from strength to bring near-term solutions for today's hardest-to-treat cancers. The Company's pipeline is led by Tumor Defense Breaker™ L-DOS47, a clin...

  2 June 2025 – TheNewswire - (Toronto, Ontario) – Helix BioPharma Corp. (TSX: “HBP”, OTC PINK: “HBPCD”, FRANKFURT: “HBP0”) (“Helix” or the “Company”), a clinical-stage oncology company shaping a near future where today's hard-to-treat cancers are vincible, today announced that the Company has appointed Rohit Babbar, CPA as Chief Financial Officer (“CFO”) of the Company, replacing James B. Murphy, CPA as Fractional CFO.   Rohit Babbar is Certified Public Accountant with fourteen years of experience leading accounting operations and financial strategy across fast-growing private and publicly listed small to mid-sized companies in Canada and the US. He is a Director at Brio Financial Group (“Brio”), a financial consulting firm that provides outsourced CFO services, financial planning and analysis, and strategic advisory support to emerging growth companies. Over the course of his career, Mr. Babbar has delivered impact across strategic growth and operational efficiency, l...

    May 20, 2025 – TheNewswire - Toronto, Ontario – Helix BioPharma Corp. (TSX: “HBP”, OTC PINK: “HBPCD”, FRANKFURT: “HBP0”) (“Helix” or the “Company”), a clinical-stage oncology company shaping a near future where today's hard-to-treat cancers are vincible, is pleased to announce that the Company has closed the acquisitions of the assets of Laevoroc Immunology AG (“Laevoroc Immunology”) and Laevoroc Chemotherapy AG (“Laevoroc Chemotherapy”), pursuant to the asset purchase agreements dated November 28, 2024, and November 30, 2024, respectively, as amended (the “Agreements”).   Acquisition of LEUMUNA™ and GEMCEDA With the closure of the Agreements, Helix has acquired substantially all the assets of Laevoroc Immunology, comprising the intellectual property, inventory, assigned agreements and rights to LEUMUNA™ (LR 09, ulodesine hemiglutarate). LEUMUNA is a pre-IND, oral inhibitor of purine nucleoside phosphorylase (PNP) developed for the treatment of leukemia rel...

  May 14, 2025 – TheNewswire - Toronto, Ontario – Helix BioPharma Corp. (TSX: “HBP”, OTC PINK: “HBPCD”, FRANKFURT: “HBP0”) (“Helix” or the “Company”), a clinical-stage oncology company shaping a near future where today's hard-to-treat cancers are vincible, announced today that it has signed an agreement with Kerentech Consulting Ltd. (“Kerentech”), under which Kerentech will support Helix in its ongoing fundraising efforts.   Under the terms of the agreement, Kerentech will assist Helix in closing a bridge financing round of USD 13 million to advance the company's lead therapeutic programs and strategic priorities through 2025 and beyond. The collaboration reflects Helix's commitment to accelerating efforts to secure a stable financial platform and fast-track the development of its pipeline candidates this year, beginning with its lead candidate, Tumor Defense Breaker™ L-DOS47.   “We're pleased to team up with Kerentech as we double down on our efforts to deliver m...

  Toronto, Ontario – TheNewswire – April 24, 2025 - Helix BioPharma Corp. (TSX: “HBP”, OTC PINK: “HBPCD”, FRANKFURT: “HBP0”) (“Helix” or the “Company”), a clinical-stage oncology company shaping a near future where today's hard-to-treat cancers are vincible, today announced the appointments of Veronika Kandziora as Chief Operating Officer (“COO”) and Jessica Kourniaktis, DPhil, as Director of Communications of the Company.   Ms. Kandziora is a seasoned executive with over 20 years of leadership experience across the biopharma, financial, and consulting sectors, bringing a rare trifecta of administrative acumen, people-centered leadership, and organizational insight to her role as COO of Helix BioPharma. Her long-standing relationship with the Company brings invaluable continuity and deep institutional knowledge to this role, having supported corporate strategy, transformation, and stakeholder engagement for Helix in Europe and North America. She previously served as Corpora...

  April 10, 2025 – TheNewswire - Toronto, Ontario – Helix BioPharma Corp. (TSX: “HBP”, OTC PINK: “HBPCD”, FRANKFURT: “HBP0”) (“Helix” or the “Company”), a clinical-stage oncology company shaping a near future where today's hard-to-treat cancers are vincible, today announced the appointment of Thomas Mehrling, MD, PhD as Chief Executive Officer (“CEO”) of the Company. A sharpening of Helix's leadership structure, outgoing CEO, Jacek Antas, will dedicate his focus to his role as Chairman of the Company, and Dr. Mehrling, who has shaped Helix's clinical strategy in his capacity as Chief Medical Officer (“CMO”), takes the helm to deliver on the Company's ambitious clinical milestones planned for 2025 and beyond.   A distinguished Hemato-Oncologist and Pharmacologist with over 20 years of experience in pharmaceutical oncology, Dr. Mehrling has a proven track record of building successful, global oncology businesses and delivering transformative therapies to the market. As ...

  April 3, 2025 – TheNewswire - Toronto, Ontario – Helix BioPharma Corp. (TSX: “HBP”, OTC PINK: “HBPCD”, FRANKFURT: “HBP0”) (“Helix” or the “Company”), a clinical-stage oncology company shaping a near future where today's hard-to-treat cancers are vincible, announces that, subject to regulatory approval, it has engaged the services of Independent Trading Group ("ITG") to provide market-making services in accordance with Toronto Stock Exchange (“TSX”) policies. ITG will trade shares of the Company on the TSX and all other trading venues with the objective of maintaining a reasonable market and improving the liquidity of the Company's common shares.   Under the agreement, ITG will receive a monthly compensation, payable in advance. The agreement is for an initial term of one month and will renew for additional one-month terms unless terminated. The agreement may be terminated by either party with 30 days' notice. There are no performance factors contained in the ag...

    March 26, 2025 - (Toronto, Ontario) – TheNewswire - Helix BioPharma Corp. (TSX: “HBP”, OTC PINK: “HBPCD”, FRANKFURT: “HBP0”) (“Helix” or the “Company”), a clinical-stage oncology company shaping a near future where today's hard-to-treat cancers are vincible, is pleased to announce the voting results from the Annual General and Special Meeting of its Shareholders (the “Meeting”) held on Wednesday, March 26, 2025. A total of 40,294,667 common shares were voted at the Meeting, representing 76.00% of Helix's total issued and outstanding shares.   Shareholders voted overwhelmingly in favor of all items of business before the Meeting. The four director nominees listed in Helix's Management Information Circular (the “Information Circular”) dated January 31, 2025, were re-elected as directors of the Company to hold office for the ensuing year or until their successors are elected or appointed. The detailed results of the vote for each director are set out below:       Ja...

  March 18, 2025 – TheNewswire - Toronto, Ontario – Helix BioPharma Corp. (TSX: “HBP”, OTC PINK: “HBPCD”, FRANKFURT: “HBP0”) (“Helix” or the “Company”), a clinical-stage oncology company shaping a near future where today's hard-to-treat cancers are vincible, announces the filing of the Company's unaudited interim financial statements as of and for the three and six month periods ended January 31, 2025 (the “Financial Statements”), the management's discussion and analysis (“MD&A”), and the certifications of the Chief Executive Officer and Chief Financial Officer (respectively, “CEO” and “CFO”) relating to the Financial Statements (collectively, the “Interim Filings”). The Interim Filings are available on the Company's profile at www.sedarplus.ca.     About Helix BioPharma Helix BioPharma Corp. is an oncology company shaping a near future where today's hard-to-treat cancers are made vincible by novel therapies that rise to the challenge. The Company in...

  March 11, 2025 – TheNewswire - Toronto, Ontario – Helix BioPharma Corp. (TSX: “HBP”, OTC PINK: “HBPCD”, FRANKFURT: “HBP0”) (“Helix” or the “Company”), a clinical-stage oncology company shaping a near future where today's hard-to-treat cancers are vincible, is pleased to announce an upcoming poster presentation highlighting the effects of Tumour Defence Breaker™, L-DOS47, in CEACAM6-expressing head and neck cancer cells and colon adenocarcinoma cells in tumor-bearing mice at the 20th European Molecular Imaging Meeting (“EMIM 2025”) taking place 11–14 March in Bilbao, Spain.   The study demonstrated that L-DOS47 effectively neutralizes the acidic tumor microenvironment (TME) in new CEACAM6-expressing solid tumors, a critical factor in tumor progression and immune evasion. In head and neck cancer and colon adenocarcinoma models, treatment with L-DOS47 raised tumor pH levels within 24 hours with a transient but measurable effect lasting up to 48 hours, effectively neutrali...

  March 6, 2025 – TheNewswire - Toronto, Ontario – Helix BioPharma Corp. (TSX: “HBP”, OTC PINK: “HBPCD”, FRANKFURT: “HBP0”) (“Helix” or the “Company”), a clinical-stage oncology company shaping a near future where today's hard-to-treat cancers are vincible, is pleased to announce the addition of three esteemed experts in oncology and drug development to its executive team. The appointments underscore Helix's commitment to assembling a world-class team to push the limits of proven science and bring life-changing therapies to patients as soon as possible.   i)Thomas Mehrling, MD, PhD – Chief Medical Officer (CMO) Dr. Thomas Mehrling (PhD in Pharmacology and MD, University of Frankfurt) brings 20 years of experience shaping the oncology landscape, with previous roles at Takeda, Mundipharma International and Roche. His track record includes the successful introduction of groundbreaking cancer drugs across Europe, with commercial successes nearing USD 1 billion in sales. As Chie...

  March 3, 2025 – TheNewswire - Toronto, Ontario – Helix BioPharma Corp. (TSX: “HBP”, OTC PINK: “HBPCD”, FRANKFURT: “HBP0”) (“Helix” or the “Company”), a clinical-stage oncology company shaping a near future where today's hard-to-treat cancers are vincible, announces that, further to its news release dated February 21, 2025, the Annual General and Special Meeting (the “Meeting”) for the year ended July 31, 2024 has been extended to March 26, 2025 to provide additional time to seek shareholder approval with respect to its proposed asset acquisitions from Laevoroc Immunology AG and Laevoroc Chemotherapy AG (the “Asset Acquisitions”), as well as a proposed financing utilizing a draw-down subscription facility structure.   The Company applied to the Ontario Superior Court of Justice for an order under section 133(3) of the Canada Business Corporations Act permitting it to hold the Meeting by March 26, 2025. The application was approved on Wednesday, February 26, 2025.   ...

February 24, 2025 - (Toronto, Ontario) – TheNewswire – Helix BioPharma Corp. (TSX: “HBP”, OTC PINK: “HBPCD”, FRANKFURT: “HBP0”) (“Helix” or the “Company”), a clinical-stage oncology company shaping a near future where today's hard-to-treat cancers are vincible, announces that its Annual General and Special Meeting (the “Meeting”) for the year ended July 31, 2024, that was to be held by January 31, 2025, has been extended to March 26, 2025 to provide additional time to seek shareholder approval with respect to its proposed asset acquisitions from Laevoroc Immunology AG and Laevoroc Chemotherapy AG (the “Asset Acquisitions”), as well as a proposed financing utilizing a draw-down subscription facility structure.   The Company has applied to the Ontario Superior Court of Justice for an order under section 133(3) of the Canada Business Corporations Act permitting it to hold the Meeting by March 26, 2025. The application is scheduled to be heard on Wednesday, February 26, 2025...

  January 9, 2025 - (Toronto, Ontario) – TheNewswire - Helix BioPharma Corp. (TSX: “HBP”, OTC PINK: “HBPCD”, FRANKFURT: “HBP0”) (“Helix” or the “Company”), a clinical-stage biopharmaceutical company developing novel therapies in immune-oncology, based on its proprietary technological CEACAM6 platform, DOS47, is pleased to announce that it has closed the private placement of 4,000,000 common shares of the Company (“Common Share”) at a price of $0.75 per Common Share for gross proceeds of CAD$3,000,000 (the “Offering”).   The Company intends to use the net proceeds of the private placement for working capital. The Offering is subject to final approval of the Toronto Stock Exchange. The Common Shares are subject to a hold period of four months and one day expiring on May 9, 2025 in accordance with applicable securities laws. In connection with the closing, the Company paid a cash fee of 10% of gross proceeds raised to an eligible finder.   About Helix BioPharma Corp. Helix Bi...

Um den gesamten Artikel unter seekingalpha.com zu lesen, klicken Sie bitte auf die Überschrift...

  Toronto, Ontario – TheNewswire – December 11, 2024 – Helix BioPharma Corp. (TSX: “HBP”, OTC PINK: “HBPCD”, FRANKFURT: “HBP0”) (“Helix” or the “Company”), a clinical-stage biopharmaceutical company developing novel and unique therapies in the field of immune-oncology, based on its proprietary technological CEACAM6 platform, DOS47, is pleased to announce the appointment of James B. Murphy as Chief Financial Officer (“CFO”) of the Company.   Mr. Murphy is a certified public accountant with over thirty years of experience in finance and operations management. He is currently a consultant with Danforth Advisors LLC (“Danforth”), a leading provider of outsourced strategic and operational specialists across functions in the life sciences industry. While at Danforth, Mr. Murphy has served over fifteen private and publicly held life sciences companies as CFO and CFO Advisor, helping them secure over USD 0.5 billion in financing and successfully execute pivotal asset transactio...

  December 6, 2024, (Toronto, Ontario) – TheNewswire – Helix BioPharma Corp. (TSX: “HBP”, OTC PINK: “HBPCD”, FRANKFURT: “HBP0”) (“Helix” or the “Company”), a clinical-stage biopharmaceutical company developing novel and unique therapies in the field of immune-oncology, based on its proprietary technological CEACAM6 platform, DOS47, announces that, further to its news releases dated November 29, 2024 and December 2, 2024, it has entered into amendment agreements with each of Laevoroc Immunology AG (“Laevoroc Immunology”) and Laevoroc Chemotherapy AG (“Laevoroc Chemotherapy”) to amend the consideration payable under the asset purchase agreements dated November 28, 2024, and November 30, 2024, respectively (the “Immunology Agreement” and the “Chemotherapy Agreement”).   Pursuant to an amendment agreement between the Company and Laevoroc Immunology dated December 5, 2024, the Company and Laevoroc Immunology have agreed to amend the Immunology Agreement to set the nu...

  December 2, 2024 – TheNewswire – (Toronto, Ontario) – Helix BioPharma Corp. (TSX: “HBP”, OTC PINK: “HBPCD”, FRANKFURT: “HBP0”) (“Helix” or the “Company”), a clinical-stage biopharmaceutical company developing novel therapies in immune-oncology, based on its proprietary technological CEACAM6 platform, DOS47, is pleased to announce it has entered into an asset purchase agreement dated November 30, 2024 (the “Agreement”) with Laevoroc Chemotherapy AG (“Laevoroc Chemotherapy”), a privately-held Swiss company.   Pursuant to the transaction (the “L-Chemo Transaction”), Helix will acquire the intellectual property, inventory, assigned agreements and rights to GEMCEDA, an oral gemcitabine chemotherapy combined with cedazuridine that near-matches the bioavailability of its intravenous counterpart, while providing a more tolerable treatment regimen for patients with prevalent, hard-to-treat cancers. Gemcitabine is a World Health Organization (WHO) Essential Medicine and GEM...

  November 29, 2024 – TheNewswire - Toronto, Ontario – Helix BioPharma Corp. (TSX: “HBP”, OTC PINK: “HBPCD”, FRANKFURT: “HBP0”) (“Helix” or the “Company”), a clinical-stage biopharmaceutical company developing novel and unique therapies in the field of immune-oncology, based on its proprietary technological CEACAM6 platform, DOS47, is pleased to announce that it has entered into an asset purchase agreement dated November 28, 2024 (the “Agreement”), with Laevoroc Immunology AG (“Laevoroc Immunology”), a privately-held, Swiss immune-oncology company.   As a result of the Transaction, Helix will acquire the intellectual property, inventory, assigned agreements and rights to LR 09, an oral immune checkpoint inhibitor in preclinical development for patients relapsing with leukemia after the intensive journey of allogeneic stem cell transplantation (SCT). LR 09 (Ulodesine hemiglutarate) is a novel, patented chemical entity discovered to be a metabolic immune checkpoint inhibito...

  (Toronto, Ontario) – TheNewswire – Helix BioPharma Corp. (TSX: “HBP”, OTC PINK: “HBPCD”, FRANKFURT: “HBP0”) (“Helix” or the “Company), a clinical-stage biopharmaceutical company developing novel and unique therapies in the field of immuno-oncology, based on its proprietary technological CEACAM6 platform, DOS47, is pleased to announce the issuance of U.S. Patent No. 11931422.   U.S. Patent No. 11931422, entitled 'Antibody-Urease Conjugates for Therapeutic Purposes', relates to Helix' first-in-class antibody-drug conjugate (ADC) platform, L-DOS47, and the optimization of conjugation ratios for a proprietary antibody that precisely binds to tumor cells expressing high levels of CEACAM6, conjugated to urease, an enzyme capable of alkalizing the acidic tumor microenvironment (TME).   CEACAM6 is a tumor antigen highly expressed on hard-to-treat, prevalent cancers where currently available treatments are not achieving meaningful enough clinical benefits for patients (including non-...